Gimv: invests in Belgian biotech firm

(CercleFinance.com) - Belgian investment company Gimv is investing 6 million euros in Belgian biotech firm Camel-IDS, the group said in a statement on Thursday.


This transaction is part of the latest financing round obtained by Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals, whereby the company secured funding of 37 million euros.

This financing will enable Camel-IDS to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, Gimv said.

Copyright (c) 2018 CercleFinance.com. All rights reserved.